Follow The Filings

BMRN Biomarin Pharmaceutical Inc.

Health Care, filed as BIOMARIN PHARMACEUTICAL INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.6%
  • $4.4M
  • 1 reduce

In 2026 Q3 Torray Investment Partners trimmed Biomarin Pharmaceutical.

Who owns this now

Largest portfolio weights among holders, up to 0.6% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners Reduce 0.58%

Who owns BMRN

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 0.58%, was 0.60% Reduce −5.3% 73,615 $4.4M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BMRN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BMRN insider trades
  • None no insider bought on the open market
  • $4.3M sold by 3 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. George Eric Davis EVP, Chief Legal Officer
    Sale
    $1.2M 17,557 shares at $66.28 22% of stake
    Traded Sep 2 Filed Sep 3
    ↗
  2. Gregory R Friberg EVP, Chief R&D Officer
    Sale
    $177K 3,281 shares at $53.85 6% of stake
    Traded May 7 Filed May 11
    ↗
  3. Charles Greg Guyer EVP, Chief Technical Officer
    Sale
    $997K 16,486 shares at $60.46 17% of stake
    Traded Mar 11 Filed Mar 12
    ↗
  4. Gregory R Friberg EVP, Chief R&D Officer
    Sale
    $382K 6,326 shares at $60.38 14% of stake
    Traded Feb 26 Filed Feb 26
    ↗
  5. George Eric Davis EVP, Chief Legal Officer
    Sale
    $1.6M 26,061 shares at $61.36 27% of stake
    Traded Feb 26 Filed Feb 26
    ↗

Also filed in the last 12 months, not counted as buying or selling: 27 stock grants and 13 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
8-K 2.02 Filing Doc
8-K 1.01 Filing Doc
8-K 8.01 Filing Doc
8-K 5.02 Filing Doc
8-K 8.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K/A 8.01,9.01 Filing Doc
8-K 5.02,5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,2.01,2.03,7.01,9.01 Filing Doc
8-K 8.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.42B $2.85B $3.22B
Gross profit * $1.9B $2.27B $2.5B
Gross margin * 78.7% 79.7% 77.7%
Net income $167.64M $426.86M $348.9M
Net margin * 6.9% 15.0% 10.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $2.96B $3.23B $3.95B
Total non-current assets * $3.89B $3.76B $3.64B
Total assets $6.84B $6.99B $7.59B
Total current liabilities $1.18B $0.607B $0.759B
Total non-current liabilities * $713.03M $723.96M $747.99M
Total equity $4.95B $5.66B $6.09B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $159.26M $572.84M $827.99M
Cash from investing -$111.24M $136.49M -$414.24M
Cash from financing -$18.73M -$526.45M -$42.39M
Net change in cash $30.6M $187.72M $368.84M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.